The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Uncovers Tet2’s Role in Resolving Inflammation

Study Uncovers Tet2’s Role in Resolving Inflammation

January 11, 2016 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Science_Research_500x270Epigenetic modifiers act on DNA by changing its chromatin and methylation status. In this way, epigenetic modifiers can define cell function. These modifiers also act to establish and maintain cell lineage via specific epigenetic status. One group of epigenetic modifiers is known as ten-eleven translocation (Tet) methylcystosine dioxygenase family members. The Tet family of genetic modifiers is able to catalyze several different DNA modifications. The nuclear Tet proteins act independently of DNA methylation and, instead, regulate chromatin architecture and gene transcription.

You Might Also Like
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
  • 2014 ACR/ARHP Annual Meeting: Fat’s Role in Inflammation
  • Aggregated Neutrophils Limit Inflammation
Also By This Author
  • CD64 May Be an RA-Specific Biomarker

Tet proteins are implicated in the immune response and have an established role as chromatin modifiers during response to lipopolysaccharide (LPS). Although little is known about how Tet proteins are able to regulate immunity and inflammation, studies have revealed that a dysfunction of Tet2 is associated with the pathogenesis of myeloid malignancies. Qian Zhang, a crystallographer at the Chinese Academy of Medical Sciences in Beijing, China, and colleagues investigated the role of Tet2 in the inflammatory response and published the results in the Sept. 17 issue of Nature. They found that Tet2 acts at the chromatin level to reduce inflammation by preventing constant transcription activation. It represses gene-specific transcription via histone deacylation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers began their investigation with innate myeloid cells and found that Tet2 played a role in the resolution of inflammation of both dendritic cells and macrophages. Specifically, Tet2 selectively and actively repressed the transcription of interleukin-6 (IL-6). The investigators next examined Tet2-deficient mice and found the knockout mice were more susceptible to endotoxic shock and dextran-sulfate-sodium-induced colitis than were wild-type mice. The knockout mice also displayed a more severe inflammatory phenotype than wild-type mice. The inflammatory phenotype included increased production of IL-6. In general, the inflammatory markers in the knockout mice tended to be up-regulated during the late phase of the response to LPS challenge—a result that was consistent with the observations from their in vitro experiments.

When the investigators over-expressed Tet2, they found that the Il6 promoter was repressed. A closer examination revealed that the IL-6-specific transcription factor IҡBξ mediated specific targeting of Tet2 to the Il-6 promoter. The result suggests that IҡBξ can have opposite regulatory roles depending on whether it is acting during the initiating phase of inflammation or the resolution phase of inflammation. When Tet2 is acting to repress the Il-6 promoter, it recruits histone deacetylase 2 (Hdac2) and represses transcription of Il-6 via histone deacylation, acting independently of DNA methylation and hydroxymethylation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: DNA, inflammation, TET protein, Tet2

You Might Also Like:
  • FOCIS 2015: TET Protein Regulation May Provide Insights for Cancer Treatment
  • 2014 ACR/ARHP Annual Meeting: Fat’s Role in Inflammation
  • Aggregated Neutrophils Limit Inflammation
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.